

# CITATION REPORT

List of articles citing

Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial

DOI: 10.1186/ar3060

Arthritis Research and Therapy, 2010, 12, R122.

Source: <https://exaly.com/paper-pdf/49720173/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
75	Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. <i>Drug Design, Development and Therapy</i> , <b>2010</b> , 4, 263-78	4.4	64
74	Clinical trials: Tight control in early RA pays off in the long run. <i>Nature Reviews Rheumatology</i> , <b>2010</b> , 6, 623-4	8.1	4
73	Efficacy assessed in follow-ups of clinical trials: methodological conundrum. <i>Arthritis Research and Therapy</i> , <b>2010</b> , 12, 132	5.7	1
72	Treatment strategies in recent onset rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , <b>2011</b> , 23, 241-4	5.3	6
71	Current world literature. <i>Current Opinion in Rheumatology</i> , <b>2011</b> , 23, 317-24	5.3	
70	Posterior cruciate ligament-retaining total knee arthroplasty in patients with rheumatoid arthritis: a concise follow-up of a previous report. <i>Journal of Bone and Joint Surgery - Series A</i> , <b>2011</b> , 93, e130(1-6)	5.6	11
69	Increasing treatment in early rheumatoid arthritis is not determined by the disease activity score but by physician global assessment: results from the CATCH study. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 2081-7	4.1	10
68	Large-joint damage in patients with early rheumatoid arthritis and its association with treatment strategy and damage of the small joints. <i>Rheumatology</i> , <b>2012</b> , 51, 2262-8	3.9	14
67	Initial management of rheumatoid arthritis. <i>Rheumatic Disease Clinics of North America</i> , <b>2012</b> , 38, 311-25	2.4	15
66	Tight disease control in early RA. <i>Rheumatic Disease Clinics of North America</i> , <b>2012</b> , 38, 327-43	2.4	10
65	My treatment approach to rheumatoid arthritis. <i>Mayo Clinic Proceedings</i> , <b>2012</b> , 87, 659-73	6.4	73
64	Disease activity assessment and patient-reported outcomes in patients with early rheumatoid arthritis. <i>Rheumatic Disease Clinics of North America</i> , <b>2012</b> , 38, 299-310	2.4	5
63	CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis. <i>PLoS ONE</i> , <b>2012</b> , 7, e38539	3.7	13
62	Response to traditional disease-modifying anti-rheumatic drugs in indigent South Africans with early rheumatoid arthritis. <i>Clinical Rheumatology</i> , <b>2012</b> , 31, 613-9	3.9	22
61	Measures in rheumatoid arthritis: are we measuring too many parameters. <i>International Journal of Rheumatic Diseases</i> , <b>2012</b> , 15, 239-48	2.3	14
60	Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 844-50	2.4	139
59	Disease activity in rheumatoid arthritis patients at initiation of biologic agents and 1 year of treatment: results from the Swiss SCQM registry. <i>Joint Bone Spine</i> , <b>2013</b> , 80, 160-4	2.9	5

58	Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target?. <i>Autoimmunity Reviews</i> , <b>2013</b> , 12, 835-8	13.6	39
57	Évaluation de l'activité de la maladie chez des patients atteints de polyarthrite rhumatoïde avant et après un an de traitements ciblés. Données issues du registre suisse SCQM. <i>Revue Du Rhumatisme (Edition Francaise)</i> , <b>2013</b> , 80, 136-141	0.1	
56	What is the best treatment strategy for early RA?. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2013</b> , 27, 523-36	5.3	6
55	Biological therapies for rheumatoid arthritis: progress to date. <i>BioDrugs</i> , <b>2013</b> , 27, 329-45	7.9	21
54	Prevention of rheumatoid arthritis: the very first steps. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 752-4	4.1	1
53	Postpublication validation of the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: where do we stand?. <i>Current Opinion in Rheumatology</i> , <b>2013</b> , 25, 157-63	5.3	15
52	The 'therapeutic window' and treating to target in rheumatoid arthritis. <i>Clinical Medicine</i> , <b>2013</b> , 13, 387-90	9.0	1
51	Current immunotherapy in rheumatoid arthritis. <i>Immunotherapy</i> , <b>2013</b> , 5, 955-74	3.8	79
50	The decline in joint replacement surgery in rheumatoid arthritis is associated with a concomitant increase in the intensity of anti-rheumatic therapy: a nationwide register-based study from 1995 through 2010. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , <b>2013</b> , 84, 331-7	4.3	69
49	Determining best practices in early rheumatoid arthritis by comparing differences in treatment at sites in the Canadian Early Arthritis Cohort. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 1823-30	4.1	24
48	Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2014</b> , 16, 430	5.7	5
47	Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews. <i>Health Technology Assessment</i> , <b>2014</b> , 18, 1-151	4.4	17
46	Prevalence and concordance of early and sustained remission assessed by various validated indices in the early arthritis "ESPOIR" cohort. <i>Joint Bone Spine</i> , <b>2014</b> , 81, 409-15	2.9	17
45	What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 861-70	2.4	182
44	Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1576-82	4.1	21
43	Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 516-21	2.4	106
42	Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1954-61	2.4	31
41	How Do We Classify Rheumatoid Arthritis in Established Disease [Can We Apply the 2010 American College of Rheumatology/European League Against Rheumatism Classification Criteria?]. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 2347-2351	4.1	1

40	Correlation of structural abnormalities of the wrist and metacarpophalangeal joints evaluated by high-resolution peripheral quantitative computed tomography, 3 Tesla magnetic resonance imaging and conventional radiographs in rheumatoid arthritis. <i>International Journal of Rheumatic Diseases</i> , <b>2015</b> , 18, 628-39	2.3	23
39	Structural integrity versus radiographic progression in rheumatoid arthritis. <i>RMD Open</i> , <b>2015</b> , 1, e000064	5.9	7
38	Prévalence et concordance de la rémission précoce et prolongée évaluée par différents indices validés de la cohorte d'arthrites débutantes « ESPOIR ». <i>Revue Du Rhumatisme (Edition Francaise)</i> , <b>2015</b> , 82, 47-53	0.1	
37	Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice. <i>Modern Rheumatology</i> , <b>2015</b> , 25, 50-5	3.3	3
36	Early rheumatoid arthritis. <b>2015</b> , 37-68		
35	Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. <i>RMD Open</i> , <b>2015</b> , 1, e000057	6.7	68
34	Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1233-40	2.4	45
33	The Efficacy and Safety of the Combination of Total Glucosides of Peony and Leflunomide for the Treatment of Rheumatoid Arthritis: A Systemic Review and Meta-Analysis. <i>Evidence-based Complementary and Alternative Medicine</i> , <b>2016</b> , 2016, 9852793	2.3	8
32	Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. <i>Lancet, The</i> , <b>2016</b> , 388, 343-355	4.0	154
31	The emerging global epidemic of paediatric inflammatory bowel disease--causes and consequences. <i>Journal of Internal Medicine</i> , <b>2016</b> , 279, 241-58	10.8	29
30	Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis. <i>RMD Open</i> , <b>2017</b> , 3, e000371	5.9	19
29	Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial. <i>Rheumatology</i> , <b>2017</b> , 56, 1586-1596	3.9	10
28	Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat-to-target therapy in daily clinical practice: results from the DREAM registry. <i>BMC Rheumatology</i> , <b>2018</b> , 2, 1	2.9	9
27	A 4-year non-randomized comparative phase-IV study of early rheumatoid arthritis: integrative anthroposophic medicine for patients with preference against DMARDs versus conventional therapy including DMARDs for patients without preference. <i>Patient Preference and Adherence</i> , <b>2018</b> , 12, 375-397	2.4	5
26	Patients' experiences of frequent encounters with a rheumatology nurse-A tight control study including patients with rheumatoid arthritis. <i>Musculoskeletal Care</i> , <b>2018</b> , 16, 305-312	1.6	7
25	Predictors of sick leave and improved worker productivity after 52 weeks of intensive treatment in patients with early rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , <b>2019</b> , 48, 271-278	1.9	3
24	Eight-year survival study of first-line tumour necrosis factor inhibitors in rheumatoid arthritis: real-world data from a university centre registry. <i>Rheumatology Advances in Practice</i> , <b>2019</b> , 3, rkz007	1.1	11
23	Cost-effectiveness of different treat-to-target strategies in rheumatoid arthritis: results from the DREAM registry. <i>BMC Rheumatology</i> , <b>2019</b> , 3, 16	2.9	4

22	Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 610-616	2.4	17
21	Response to: 'Metering the METEOR in methotrexate failure: is propensity score a falling star?' by Ahmed. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, e132	2.4	
20	Early Targeted Combination Treatment With Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Long-Term Outcomes in Rheumatoid Arthritis: Ten-Year Follow-Up Results of a Randomized Clinical Trial. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 1450-1458	4.7	3
19	Therapeutic Options and Cost-Effectiveness for Rheumatoid Arthritis Treatment. <i>Current Rheumatology Reports</i> , <b>2020</b> , 22, 44	4.9	6
18	Treatment strategies are more important than drugs in the management of rheumatoid arthritis. <i>Clinical Rheumatology</i> , <b>2020</b> , 39, 1363-1368	3.9	22
17	Treat-to-Target Strategies in Rheumatoid Arthritis: a Systematic Review and Cost-Effectiveness Analysis. <i>SN Comprehensive Clinical Medicine</i> , <b>2021</b> , 3, 838-854	2.7	0
16	Switching from TNF inhibitor to tacrolimus as maintenance therapy in rheumatoid arthritis after achieving low disease activity with TNF inhibitors and methotrexate: 24-week result from a non-randomized, prospective, active-controlled trial. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 182	5.7	
15	Intensive therapy for moderate established rheumatoid arthritis: the TITRATE research programme. <i>Programme Grants for Applied Research</i> , <b>2021</b> , 9, 1-186	1.5	0
14	Determining the Lowest Optimally Effective Methotrexate Dose for Individual RA Patients Using Their Dose Response Relation in a Tight Control Treatment Approach. <i>PLoS ONE</i> , <b>2016</b> , 11, e0148791	3.7	8
13	The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , <b>2017</b> , 21, 1-258	4.4	27
12	Is non-biological treatment of rheumatoid arthritis as good as biologics?. <i>World Journal of Orthopedics</i> , <b>2015</b> , 6, 278-83	2.2	9
11	Nonimmunosuppressive disease-modifying antirheumatic drugs. <b>2015</b> , 434-442		1
10	The impact of anti-cyclic citrullinated peptide antibody status on the management of patients with early rheumatoid arthritis: observational study results from Lithuania. <i>Acta Medica Lituanica</i> , <b>2018</b> , 25, 112-123	0.7	2
9	Rheumatoid arthritis : a joint venture. <i>South African General Practitioner</i> , <b>2020</b> , 1, 193-195	0.1	
8	Budget impact analysis of an early identification and referral model for diagnosing patients with suspected rheumatoid arthritis in Ireland. <i>Rheumatology Advances in Practice</i> , <b>2020</b> , 4, rkaa059	1.1	
7	Short-term glucocorticoids for flares in people with rheumatoid arthritis receiving disease-modifying anti-rheumatic drugs (DMARDs). <i>The Cochrane Library</i> , <b>2021</b> , 2021,	5.2	2
6	Short-term induction glucocorticoids and disease-modifying anti-rheumatic drugs (DMARD) therapy for rheumatoid arthritis. <i>The Cochrane Library</i> , <b>2021</b> , 2021,	5.2	2
5	Relationship between laboratory biomarkers and ultrasonographic signs of inflammation in patients with rheumatoid arthritis treated with a rituximab biosimilar. <i>Sovremennaya Revmatologiya</i> , <b>2022</b> , 16, 29-36	0.7	

- 4 Predictors of flare in rheumatoid arthritis patients with persistent clinical remission/low disease activity: Data from the TARAC cohort. **2022**, 101, e29974
- 3 The role of monitoring the level of matrix metalloproteinase 3 in patients with rheumatoid arthritis on anti-B-cell therapy. **2022**, 60, 473-480
- 2 Right Treatment to the Right Patient in Moderate-to-Severe Psoriasis: Discussion on Difference. 2-11
- 1 Frequency of joint inflammation is associated with local joint damage progression in rheumatoid arthritis despite long-term targeted treatment. **2023**, 9, e002552